Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis

Jennifer Chae-Kim,1,2 Gunjal Garg,3 Larisa Gavrilova-Jordan,4 Lindsay E Blake,5 Tongil "TI" Kim,6 Qiang Wu,7 Clifford C Hayslip8

HIGHLIGHTS
- Women who receive progestin and metformin therapy have lower disease relapse than those receiving progestin alone.
- Combined therapy was not associated with significantly different remission rates.
- Combined therapy was not associated with significantly different pregnancy and live birth rates.

ABSTRACT
Objective Progestin therapy is the recommended fertility-sparing management of atypical endometrial hyperplasia or early-stage endometrial cancer in reproductive-aged women. Our objective was to evaluate disease relapse after progestin and metformin versus progestin therapy alone in patients with endometrial hyperplasia or cancer. Our secondary outcomes were disease remission, clinical pregnancy and live birth rate.

Methods A systematic review of the literature was conducted (MEDLINE, Web of Science, Cochrane Library, CINAHL, LILACS, clinicaltrials.gov) from inception to April 2021. Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management were included in the review. Early endometrial cancer was defined as grade 1, stage 1 disease. Exclusion criteria included women with higher grade endometrial cancer and when conservative management was not for fertility-sparing purposes. Data are presented as odds ratios (ORs) and 95% confidence intervals (CIs) with fixed or random effects meta-analysis. Quality scoring was based on the Newcastle-Ottawa and Jadad scales.

Results In total, 271 reports were identified and six studies met the inclusion criteria. These studies included 621 women; 241 (38.8%) patients received combined therapy and 380 (61.2%) received progestin therapy alone. Relapse rates were lower for progestin and metformin than for progestin therapy alone (pooled OR 0.46, 95% CI 0.24 to 0.91, p=0.03). The remission rates were not different (pooled OR 1.35, 95% CI 0.91 to 2.00, p=0.06). Women who received progestin and metformin achieved pregnancy and live birth rates similar to those who received progestin therapy only (pooled OR 1.01, 95% CI 0.44 to 2.35, p=0.98; pooled OR 0.46, 95% CI 0.21 to 1.03, p=0.06).

Conclusion For reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer, progestin and metformin therapy compared with progestin therapy alone is associated with lower relapse rates, and similar remission, clinical pregnancy and live birth rates.

PROSPERO registration number CRD42020179069.
definitive therapy in the hope of having children, and they bring attention to the need for a new therapeutic strategy. Metformin, a biguanide antidiabetic agent, has recently been repurposed for the management of endometrial cancer because of its anti-proliferative effects on endometrial cells. Metformin has also been shown to have a synergistic impact on progesterone’s inhibitory effect on endometrial cell proliferation. Growing evidence in the literature suggests that metformin may be a beneficial adjunctive therapy, with a synergistic effect alongside progesterin, in the suppression of endometrial proliferation.

A 2017 Cochrane systematic review reported on three studies that studied the effects of metformin on endometrial hyperplasia; only one of these studies compared the effects of progestin and metformin with progesterin alone. Since then, additional studies have been added to the literature, and have also examined outcomes for patients with atypical hyperplasia and those with endometrial carcinoma. Although atypical endometrial hyperplasia is a pre-cancerous disease state, there is significant overlap between patients with atypical hyperplasia and those found to have invasive carcinoma after hysterectomy. Given this risk of underlying undiagnosed malignancy, or progression to cancer, the standard of care for both subsets of patients is hysterectomy. Additionally, both subsets of patients may be eligible for fertility-sparing management. The aim of this study was to conduct an updated systematic review of outcomes for fertility-sparing management of atypical endometrial hyperplasia and early endometrial cancer with progesterin and metformin (‘combined’) versus progesterin therapy alone.

METHODS

Search Strategy

We followed updated PRISMA guidelines for systematic reviews. A literature search was conducted by a medical librarian (LEB) identifying studies in PubMed MEDLINE, Web of Science, Cochrane Library, CINAHL, LILACS, and clinicaltrials.gov. These databases were searched from inception to April 2020 using key terms and subject headings when available. The same search was updated in April 2021. The full search strategy for PubMed is presented in the Online supplemental table 1. References of primary and review articles were hand-searched to identify any other relevant studies not captured by the database search, however no new additional studies were included. Unpublished and gray literature were not included in the literature review. The primary outcome of interest was disease relapse. Secondary outcomes included disease remission, clinical pregnancy, and live birth rate.

Study Selection

Studies were selected if they met the inclusion criteria as follows: reproductive-aged women with a histologically confirmed diagnosis of atypical endometrial hyperplasia or early endometrial cancer, who met criteria for fertility-sparing management, and received fertility-sparing management with combined therapy or progesterin therapy. Studies reporting on at least one of the outcomes were included in the meta-analysis. Relevant exclusion criteria included women with endometrial cancer classified as grade 2 or worse, and when conservative management was pursued due to poor surgical candidacy or perioperative morbidity. Interventional randomized or non-randomized trials and observational prospective or retrospective studies were included. Case reports or series, editorial letters, and conference presentations were excluded from the analysis. If part of the study population met the inclusion criteria, however, patient-level data could not be distinguished from those who did not meet the inclusion criteria after full-text analysis or correspondence with the senior author, the study was excluded from the meta-analysis. The complete review protocol was registered with PROSPERO under the registration number CRD42020179069 and can be accessed online at https://www.crd.york.ac.uk/prospero/.

Data Extraction

Studies were selected and screened by two reviewers independently (JC-K and GG), with a third reviewer (CH) designated as a final consultant for any disagreements. The records were screened based on titles and abstracts. Full-text articles were then assessed for eligibility based on inclusion and exclusion criteria by the authors listed above. Extracted data, if available, included age, reported patient characteristics such as body mass index, race or ethnicity, medical history, histological diagnosis, primary and secondary outcomes. Data were kept on a Google spreadsheet. Inquiries regarding missing data were sent to corresponding authors. Yang and colleagues provided updated data regarding live birth outcomes, and these were incorporated into our analysis. Data that could not be retrieved after contacting authors on two separate occasions were not included in the analysis. In accordance with the journal’s guidelines, we will provide our data for the reproducibility of this study in other centers if such requested.

Quality Assessment of the Studies

Study quality was evaluated using the Newcastle-Ottawa Scale for non-randomized studies, and the Jadad scale for randomized trials. Based on the Newcastle-Ottawa scale, we assigned 0–9 points to three criteria: selection, comparability, and outcome assessment. Based on the Jadad scale for randomized studies, we assigned 0–5 points to three criteria: randomization, blinding, and an account of all patients.

Statistical Analysis

Data were analyzed independently by two authors (TK and QW) using Stata 14.0 and R statistical computing software, respectively. A random-effects meta-analysis model was selected to evaluate the pooled OR of primary outcomes when there was statistical heterogeneity in at least five unique studies. Otherwise, the fixed-effect model was employed. Data are presented as odds ratio (ORs) with 95% confidence intervals (CIs). A P value<0.05 was considered to indicate statistical significance. Subgroup analysis by study type, comparing randomized trials with retrospective studies, was pursued as well.

RESULTS

Study Characteristics

The initial literature search yielded 251 reports, and the updated search in April 2021 yielded an additional 20 reports, making a total of 271 reports. No additional studies were identified after review of the reference lists of primary and review articles. After removing duplicate records and an initial screen of citations and abstracts, 206 articles were excluded and 54 full-text articles were examined. Ultimately, six studies met the inclusion criteria for
The PRISMA flow chart describing the selection process is presented in Figure 1.

These six studies reported data on 621 women; 241 (38.8%) patients who received combined therapy, and 380 (61.2%) patients who received progestin therapy alone. Four studies were retrospective17–19 21 and two were randomized clinical trials.14 20 For all studies, the diagnosis of atypical endometrial hyperplasia or endometrial carcinoma was histologically determined. Most of the study population, specifically 472 (76%) women, had been diagnosed with atypical endometrial hyperplasia, and 149 (24%) women had endometrial cancer. Studies did not consistently distinguish between these groups of patients when reporting data, and did not report outcomes in a diagnosis-specific manner.

Mean age and body mass index for the combined therapy group were 33.8 years and 31.9 kg/m² compared with 34.6 years and 27.5 kg/m² in the progestin group. Studies did not uniformly report summary statistics and SD could not be calculated for age or body mass index. Both combined therapy and progestin therapy alone groups had a high percentage of nulliparous women at 78.9% and 78.3%, respectively. The duration of metformin therapy was reported by three studies14 17 18 and ranged from 6 months14 to 18 months,17 or until conception or disease recurrence.18 Three studies reported adverse effects of treatment,14 18 20 noting the most common adverse effects of metformin were nausea or diarrhea, and that few patients discontinued therapy due to adverse effects. Two studies reported hormone receptor status19 20; in one study, the histological evaluation of all patients in the study revealed positive estrogen and progesterone receptors19; another study reported minimal difference in expression of estrogen and progesterone receptors before and after therapy with either progestin or combined treatment.20 The main characteristics of the included studies are shown in Table 1.

Quality Assessment
For studies evaluated on the Newcastle-Ottawa Scale, the final quality assessment scores ranged from 7 to 8, and the average score was 7.25. For studies evaluated on the Jadad scale, the assessment scores ranged from 3 to 4, and the average score was 3.5.

Meta-analysis
Primary Outcome: Relapse
A meta-analysis of three studies found that the odds of relapse were statistically lower for combined therapy compared with progestin therapy alone (pooled OR 0.46, 95% CI 0.24 to 0.91, p=0.03). Two of the studies were retrospective17 18 and one was a randomized trial.14 Subgroup analysis was performed for retrospective studies only, and the relapse rate was found to be statistically lower for combined therapy (OR 0.30, 95% CI 0.13 to 0.72, p<0.01). See Figure 2.

Secondary Outcomes: Remission, Clinical Pregnancy, Live Birth Rate
Meta-analysis of all six studies found that the OR for remission was not statistically different between combined and progestin therapy (p=0.11). However, for clinical pregnancy and live birth rate, the meta-analysis showed a statistically significant advantage for combined therapy (p=0.019).
<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Region</th>
<th>Design</th>
<th>Total No of patients</th>
<th>No of patients in treatment groups</th>
<th>Intervention dosage</th>
<th>Age at diagnosis (years)*</th>
<th>Histological diagnosis, n (%)</th>
<th>Reported outcomes</th>
<th>Median follow-up (months)</th>
<th>Study period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matsuo et al (2020)</td>
<td>USA</td>
<td>Retrospective, single institution</td>
<td>245</td>
<td>Prog: 194 (140 oral, 54 IUD)</td>
<td>MPA, MA, NE, Depo, LNG-IUD; dosages not specified</td>
<td>36 (30–43) for oral progestin; 36 (29.8–44.3) for IUD</td>
<td>AEH</td>
<td>Remission</td>
<td>9.0</td>
<td>2003–2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prog + M: 51 (36 oral, 15 IUD)</td>
<td>As above, metformin; dosages not specified</td>
<td>35 (27–41) for oral progestin; 34 (23–39) for IUD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acosta-Torres et al (2020)</td>
<td>USA</td>
<td>Retrospective, multi-institution</td>
<td>92</td>
<td>Prog: 58</td>
<td>MA 80–160 mg daily, MPA 10–40 mg daily, prometrium 400 mg daily, or LNG-IUD 52 mg</td>
<td>36 (31–39)</td>
<td>AEH: 33 (56.9%); EC: 25 (43.1%)</td>
<td>Remission, relapse, live births, 5 year recurrence free survival</td>
<td>28.4</td>
<td>1999–2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prog + M: 34</td>
<td>As above, metformin 500–1000 mg daily</td>
<td>32 (29–35)</td>
<td>AEH: 21 (61.8%); EC: 13 (38.2%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang et al (2020)</td>
<td>China</td>
<td>Randomized trial (open label), single institution</td>
<td>150</td>
<td>Prog: 74</td>
<td>MA 160 mg daily</td>
<td>33.4±5.2</td>
<td>AEH: 62 (83.8%); EC: 12 (16.2%)</td>
<td>Remission, relapse, pregnancy, live births, adverse effects</td>
<td>33.4, until Feb 2019</td>
<td>2013–2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prog + M: 76</td>
<td>As above, metformin 500 mg three times a day</td>
<td>32±4.5</td>
<td>AEH: 61 (80.3%); EC: 15 (19.7%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prog + M: 63</td>
<td>MPA 400 mg daily, metformin 750–2250 mg daily</td>
<td>35 (26–44)</td>
<td>AEH: 21 (33.3%); EC: 42 (66.7%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prog + M: 9</td>
<td>As above, metformin 250 mg three times a day</td>
<td>34±7.1</td>
<td>AEH</td>
<td>Remission, relapse, pregnancy rates, live birth rates, adverse effects</td>
<td>12, until Jan 2014</td>
<td>2012–2013</td>
</tr>
<tr>
<td>Shan et al (2014)</td>
<td>China</td>
<td>Randomized trial, single institution, pilot study</td>
<td>16</td>
<td>Prog: 8</td>
<td>MA 160 mg daily</td>
<td>36.4±4.2</td>
<td>AEH</td>
<td>Remission, relapse, pregnancy rates, live birth rates, adverse effects</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prog + M: 8</td>
<td>As above, metformin 500 mg three times a day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Mean±SD, or median with IQR.
†Twenty-three patients with endometrial carcinoma were used as historical controls, with study period from 1996 to 2017.

AEH, atypical endometrial hyperplasia; Depo, intramuscular depo-medroxyprogesterone acetate; EC, endometrial carcinoma; LNG-IUD/IUD, levonorgestrel intrauterine device; MA, megestrol acetate; MPA, medroxyprogesterone acetate; NE, norethindrone; Prog, progestin therapy; Prog+M, progestin and metformin combined therapy.
A Relapse

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Events</th>
<th>Total</th>
<th>Control Total</th>
<th>Odds Ratio</th>
<th>OR</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitsuhasi, 2019</td>
<td>8</td>
<td>61</td>
<td>10</td>
<td>20</td>
<td>0.15</td>
<td>[0.05; 0.48]</td>
<td>53.0%</td>
</tr>
<tr>
<td>Acosta–Torres, 2020</td>
<td>4</td>
<td>23</td>
<td>10</td>
<td>40</td>
<td>0.63</td>
<td>[0.17; 2.30]</td>
<td>24.4%</td>
</tr>
<tr>
<td>Yang, 2020</td>
<td>7</td>
<td>52</td>
<td>6</td>
<td>45</td>
<td>1.01</td>
<td>[0.31; 3.26]</td>
<td>22.8%</td>
</tr>
<tr>
<td><strong>Total [95% CI]</strong></td>
<td><strong>136</strong></td>
<td><strong>105</strong></td>
<td></td>
<td><strong>46</strong></td>
<td>0.46</td>
<td>[0.24; 0.91]</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heterogeneity: $I^2 = 64%$, $t^2 = 0.6747$, $p = 0.06$</td>
<td>Test for overall effect: $z = -2.23$ ($p = 0.03$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B Remission

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Events</th>
<th>Total</th>
<th>Control Total</th>
<th>Odds Ratio</th>
<th>OR</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shan, 2014</td>
<td>6</td>
<td>8</td>
<td>2</td>
<td>8</td>
<td>9.00</td>
<td>[0.94; 86.52]</td>
<td>1.2%</td>
</tr>
<tr>
<td>Zhou, 2015</td>
<td>8</td>
<td>9</td>
<td>19</td>
<td>23</td>
<td>1.68</td>
<td>[0.16; 17.52]</td>
<td>2.8%</td>
</tr>
<tr>
<td>Mitsuhasi, 2019</td>
<td>61</td>
<td>63</td>
<td>20</td>
<td>23</td>
<td>4.58</td>
<td>[0.71; 29.36]</td>
<td>2.2%</td>
</tr>
<tr>
<td>Acosta–Torres, 2020</td>
<td>23</td>
<td>34</td>
<td>40</td>
<td>58</td>
<td>0.94</td>
<td>[0.38; 2.33]</td>
<td>22.5%</td>
</tr>
<tr>
<td>Matsuo, 2020</td>
<td>30</td>
<td>51</td>
<td>107</td>
<td>194</td>
<td>1.16</td>
<td>[0.62; 2.17]</td>
<td>43.2%</td>
</tr>
<tr>
<td>Yang, 2020</td>
<td>52</td>
<td>70</td>
<td>45</td>
<td>66</td>
<td>1.35</td>
<td>[0.64; 2.84]</td>
<td>28.1%</td>
</tr>
<tr>
<td><strong>Total [95% CI]</strong></td>
<td><strong>235</strong></td>
<td><strong>372</strong></td>
<td></td>
<td><strong>135</strong></td>
<td>1.35</td>
<td>[0.91; 2.00]</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heterogeneity: $I^2 = 4%$, $t^2 = 0.0128$, $p = 0.39$</td>
<td>Test for overall effect: $z = 1.47$ ($p = 0.14$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C Clinical pregnancy

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Events</th>
<th>Total</th>
<th>Control Total</th>
<th>Odds Ratio</th>
<th>OR</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhou, 2015</td>
<td>3</td>
<td>8</td>
<td>6</td>
<td>13</td>
<td>0.70</td>
<td>[0.12; 4.23]</td>
<td>26.5%</td>
</tr>
<tr>
<td>Yang, 2020</td>
<td>19</td>
<td>37</td>
<td>15</td>
<td>31</td>
<td>1.13</td>
<td>[0.43; 2.93]</td>
<td>73.5%</td>
</tr>
<tr>
<td><strong>Total [95% CI]</strong></td>
<td><strong>45</strong></td>
<td><strong>44</strong></td>
<td></td>
<td><strong>101</strong></td>
<td>1.01</td>
<td>[0.44; 2.35]</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heterogeneity: $I^2 = 0%$, $t^2 = 0$, $p = 0.65$</td>
<td>Test for overall effect: $z = 0.03$ ($p = 0.98$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D Live birth rate

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Events</th>
<th>Total</th>
<th>Control Total</th>
<th>Odds Ratio</th>
<th>OR</th>
<th>95%–CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acosta–Torres, 2020</td>
<td>2</td>
<td>34</td>
<td>14</td>
<td>58</td>
<td>0.20</td>
<td>[0.04; 0.93]</td>
<td>51.5%</td>
</tr>
<tr>
<td>Yang, 2020</td>
<td>13</td>
<td>37</td>
<td>13</td>
<td>31</td>
<td>0.75</td>
<td>[0.28; 2.00]</td>
<td>48.5%</td>
</tr>
<tr>
<td><strong>Total [95% CI]</strong></td>
<td><strong>71</strong></td>
<td><strong>89</strong></td>
<td></td>
<td><strong>46</strong></td>
<td>0.46</td>
<td>[0.21; 1.03]</td>
<td>100.0%</td>
</tr>
<tr>
<td>Heterogeneity: $I^2 = 52%$, $t^2 = 0.4810$, $p = 0.15$</td>
<td>Test for overall effect: $z = -1.90$ ($p = 0.06$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2  Odds ratios of outcomes.

therapy (pooled OR 1.35, 95% CI 0.91 to 2.00, $p=0.14$). A meta-analysis of two studies found the odds of clinical pregnancy for combined therapy did not significantly differ from that of progestin therapy alone (OR 1.01, 95% CI 0.44 to 2.35, $p=0.98$). A meta-analysis of two studies found the odds of live birth for combined versus progestin therapy groups were not statistically different at the 0.05 level, although combined therapy was associated with a lower odds of live birth that was marginally significant at the 0.1 level (pooled OR 0.46, 95% CI 0.21 to 1.03, $p=0.06$). Subgroup analysis of retrospective studies showed that the OR for remission was not significantly different between the two groups. Subgroup analysis of pregnancy and live birth rate outcomes was not meaningful due to the limited number of studies.
DISCUSSION

Summary of Main Results

This study provides an overview of the current evidence on the outcomes of fertility-sparing therapy with progestin and metformin versus progestin alone for atypical endometrial hyperplasia and early endometrial cancer in reproductive-aged women. While remission rates were not significantly different, relapse rates were statistically lower for women who received combined therapy than those who received progestin therapy alone. Women who received progestin and metformin achieved pregnancy and live birth rates similar to those who received progestin only.

Results in the Context of Published Literature

Investigation of this novel treatment strategy has clinical relevance with the rising incidence of endometrial cancer in young, reproductive-aged women who require fertility-sparing treatment. Conservative management involves progestin therapy, which has been shown in many studies to be associated with high recurrence or relapse rates, reported around 25%–40%.6 Our meta-analysis of relapse rates in women who received combined therapy were significantly lower compared with those who received progestin therapy only. Metformin has been shown to modulate expression of steroid receptors, having the effect of decreasing estrogen receptor downregulation of progesterone receptor expression, metformin-mediated upregulation of progesterone receptor may contribute to our findings of significantly lower relapse rates.

Our study did not find significant differences in reproductive outcomes of clinical pregnancy or live birth rate based on a limited number of studies. Combined progestin and metformin therapy was associated with a lower live birth rate that was marginally significant, indicating the need for further research. It was difficult to ascertain from the available data whether patients receiving metformin were more likely to have infertility, or some other underlying pathology that may contribute to infertility. Matsuo and colleagues examined characteristics associated with metformin use and found that women who received metformin were in fact more likely to have diabetes, hyperlipidemia or polycystic ovary syndrome.21 Further, given that women with polycystic ovary syndrome or diabetes mellitus are more likely to develop atypical endometrial hyperplasia or endometrial cancer, there may have been selection bias in the study population.

While the clinical pregnancy rates of the two groups were not significantly different, the pregnancy rates for our study (54% for progestin and metformin combined therapy, 48% for progestin therapy alone) appear higher than what has been previously reported (approximately 34%–41%).4 6 We suspect this difference may be due to higher utilization of assisted reproductive technology. Not all studies reported on assisted reproduction versus spontaneous pregnancy, however it appears a vast majority of study participants pursued assisted reproduction. Two studies17 19 reported the proportion of clinical pregnancies that required assisted reproduction, and this ranged from 81% to 89%. This proportion is substantially higher than the 54.1% of women who achieved clinical pregnancy by way of assisted reproductive technology, as reported in an earlier systematic review.3 Assisted reproductive technology is often recommended for patients undergoing fertility-sparing therapy, given the risk of relapse. Our findings of lower relapse rates for women on combined progestin and metformin therapy suggest that this therapy may be beneficial and should be considered for patients who face barriers to timely entry to infertility care.

Strengths and Weaknesses

The main strength of this study is that it is the first systematic review and meta-analysis of this topic that examines outcomes after progestin and metformin therapy for patients with endometrial hyperplasia and cancer. This review provides insight into outcomes related to a new treatment regimen and identifies areas for future research. There are a number of limitations to this meta-analysis. First, there were a limited number of studies meeting the inclusion criteria. Many of the included studies reported outcomes for both atypical endometrial hyperplasia and endometrial carcinoma, without distinguishing between these groups, therefore the meta-analysis reports outcomes for these patients together. Further, a majority of the included patients had atypical endometrial hyperplasia, and this may skew the results. There may be a number of confounding factors such as age, race or ethnicity, body mass index, or baseline fertility status. We were unable to statistically compare the body mass indices of women who received combined versus progestin therapy alone due to missing data in multiple studies. From the available data, however, the average body mass index for women who received combined therapy appears higher (31.9 kg/m²) than that of those who received progestin therapy only (27.5 kg/m²). In light of research indicating that patients with endometrial cancer with higher body mass index have poorer outcomes including relapse,26 the decreased relapse rates seen in the combined therapy group is encouraging.

Other important limitations are variations in the administration of progestin and metformin. There was heterogeneity in the progestin type utilized in the included studies. One of the included studies compared systemic oral progestin with local progestin intrauterine device, and found that metformin was more effective with local progestin.21 Other research has shown no significant difference in endometrial hyperplasia or cancer response outcomes when comparing systemic versus local effects of progestin.27 The doses of metformin ranged from 500mg daily to 2250mg daily, or was unspecified. Only three studies reported on duration of metformin therapy. In one study, about a quarter of the patients who received combined therapy continued metformin for a mean of 18.3 months,17 and other studies reported that patients continued metformin for at least 6 months if they did not achieve complete remission.14 or until conception or disease recurrence.18 More studies are needed to determine the optimal window between discontinuation of combined progestin and metformin therapy and onset of pregnancy.

Implications for Practice and Future Research

The implications of our findings for clinical practice are still uncertain. Further prospective, randomized investigation is needed to overcome the limitations of this study.

CONCLUSIONS

In conclusion, this meta-analysis shows that combined progestin and metformin therapy is associated with decreased disease
relapse rates. Disease remission, clinical pregnancy, and live birth rates were similar for patients who received progesterin and metformin versus progesterin therapy. A review of the literature included a limited number of moderate quality studies, indicating the need for further research.

Author affiliations
6Department of Marketing, Naveen Jindal School of Management, The University of Texas at Dallas, Richardson, Texas, USA
7Department of Biostatistics, East Carolina University, Greenville, North Carolina, USA
8Department of Biostatistics, East Carolina University, Greenville, North Carolina, USA
9Department of Obstetrics and Gynecology, Baylor Scott & White Health, and Brody School of Medicine at East Carolina University, and Vidant Medical Center for supporting this research.

Acknowledgements The authors would like to acknowledge the Departments of Obstetrics and Gynecology at Texas A&M College of Medicine, at Baylor Scott & White Health, and Brody School of Medicine at East Carolina University and, and Vidant Medical Center for supporting this research.

Contributors JC-K: conceptualization, methodology, validation, investigation, writing – original draft, writing – review & editing, visualization, project administration, guarantor. GD: methodology, verification, writing – review & editing. CCH: writing – review & editing, visualization, supervision.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

REFERENCES